Anti-AARSD1 Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-AARSD1 Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-AARSD1 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-AARSD1 Magnetic Beads-IP Kit Product Description
The Anti-AARSD1 magnetic Beads, conjugated with Anti-AARSD1 antibody, are used for immuneprecipitation (IP) of AARSD1 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing AARSD1 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound AARSD1 proteins are dissociated from the magnetic beads using an elution buffer. Anti-AARSD1 Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Human AARSD1 protein (Catalog#14280-H07E)
Species Reactivity
Human AARSD1
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Human AARSD1 (rh AARSD1; Catalog#14280-H07E; Q9BTE6-2; Thr176-Glu525). AARSD1 specific IgG was purified by Human AARSD1 affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-AARSD1 Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-AARSD1ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
AARSD1 Background Information
AARSD1 belongs to the class-II aminoacyl-tRNA synthetase family, Alax-L subfamily. AARSD1 binds 1 zinc ion per subunit functions in trans to edit the amino acid moiety from incorrectly charged tRNA(Ala). Four transcript variants have been described for AARSD1: NM_25267.3, NM_113642.2, NM_1142653.1 and NM_1142654.1. It has been determined that the latter two variants represent a distinct upstream locus, which is now represented by GeneID:1885848 (PTGES3L), while the former two variants represent readthrough transcripts between PTGES3L and this locus (AARSD1). The readthrough locus (PTGES3L-AARSD1) is now represented by GeneID:188585.
Full Name
alanyl-tRNA synthetase domain containing 1
References
Tatham MH, et al. (2011) Comparative proteomic analysis identifies a role for SUMO in protein quality control. Oncogene. 19(17):2120-8. Kim W, et al. (2011) Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell. 44(2):325-40. Udeshi ND, et al. (2012) Methods for quantification of in vivo changes in protein ubiquitination following proteasome and deubiquitinase inhibition. Mol Cell Proteomics. 11(5):148-59.
新浪微博
腾讯微博
QQ空间
客服
